Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 16 Oct 2017 Planned End Date changed from 1 Mar 2018 to 1 Jul 2018.
- 16 Oct 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jul 2018.
- 20 Jan 2017 Planned number of patients changed from 187 to 188.